Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $60
Daily short sale tracking: Ambev SA's short volume increased by 4 million, with a short sale ratio of 10%
J&J Releases Encouraging Data on Talvey Combination Therapies
Bristol-Myers Squibb Options Spot-On: On September 27th, 99,897 Contracts Were Traded, With 833.89K Open Interest
Unusual Options Activity: UGI, TSLA and Others Attract Market Bets, UGI V/OI Ratio Reaches 197.4
Expand
MARKET-TEST-DUMMY : looks little sideways first